Probiotics for children with uncomplicated severe acute malnutrition (PruSAM study): A randomized controlled trial in the Democratic Republic of Congo

Kambale, Richard Mbusa; Ntagazibwa, Joseph Ntagerwa; Kasengi, Joe Bwija; Zigashane, Adrien Burume; Francisca, Isia Nancy; Mashukano, Benjamin Ntaligeza; Ngaboyeka, Gaylord; Bahizire, Esto; Zech, Francis; Bindels, Laure B.; Linden, Dimitri van der

doi:10.1016/j.ajcnut.2023.01.019

Cited by 8 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result, the future of probiotics [154] and prebiotics should include emphasizing the need for standardized testing methods and personalized approaches to optimize their effectiveness [155][156][157]. There is a relationship between prebiotics, the gut microbiota, and metabolic risks, suggesting that prebiotic consumption could potentially improve metabolic health through modulation of the gut microbiota [158][159][160][161].…”

Section: Discussionmentioning

confidence: 99%

Modulation of the Gut Microbiota with Prebiotics and Antimicrobial Agents from Pleurotus ostreatus Mushroom

Törős

El-Ramady

Prokisch

et al. 2023

Foods

View full text Add to dashboard Cite

Pleurotus ostreatus (Jacq. ex Fr.) P. Kumm mushroom contains bioactive compounds with both antimicrobial and prebiotic properties, which are distributed in the mushroom mycelium, fruiting body, and spent substrate. The mushroom is rich in nondigestible carbohydrates like chitin and glucan, which act as prebiotics and support the growth and activity of beneficial gut bacteria, thereby maintaining a healthy balance of gut microbiota and reducing the risk of antibiotic resistance. The bioactive compounds in P. ostreatus mushrooms, including polysaccharides (glucans, chitin) and secondary metabolites (phenolic compounds, terpenoids, and lectins), exhibit antibacterial, antiviral, and antifungal activities. When mushrooms are consumed, these compounds can help preventing the growth and spread of harmful bacteria in the gut, reducing the risk of infections and the development of antibiotic resistance. Nonetheless, further research is necessary to determine the efficacy of P. ostreatus against different pathogens and to fully comprehend its prebiotic and antimicrobial properties. Overall, consuming a diet rich in mushroom-based foods can have a positive impact on human digestion health. A mushroom-based diet can support a healthy gut microbiome and reduce the need for antibiotics.

show abstract

Section: Discussionmentioning

confidence: 99%

Modulation of the Gut Microbiota with Prebiotics and Antimicrobial Agents from Pleurotus ostreatus Mushroom

Törős

El-Ramady

Prokisch

et al. 2023

Foods

View full text Add to dashboard Cite

show abstract

“…An increasing number of studies have been conducted to clarify the function of L. reuteri in diarrhea since Shornikova and his colleagues first analyzed the effectiveness of L. reuteri DSM 17938 in pediatric acute watery diarrhea and demonstrated that it can dosage-dependently shorten the duration of acute watery diarrhea (Shornikova et al, 1997a;Shornikova et al, 1997b). Previous nine RCTs, which demonstrated that L. reuteri DSM 17938 was capable of reducing the frequency, length of time, and incidence of diarrhea in children and adults, especially in those with lower nutritional status, supported the drug's potential benefits in treating and preventing diarrheal diseases (Agustina et al, 2012;Francavilla et al, 2012;Jones et al, 2013;Dinleyici et al, 2014;Gutierrez-Castrellon et al, 2014;Dinleyici et al, 2015;Pernica et al, 2017;Maragkoudaki et al, 2018;Kambale et al, 2023). Additionally, L. reuteri DSM 17938 could shorten a child's stay in the hospital due to acute gastroenteritis or infectious diarrhea (Dinleyici et al, 2014;Szymanski and Szajewska, 2019).…”

Section: Diarrheamentioning

confidence: 95%

Lactobacillus reuteri in digestive system diseases: focus on clinical trials and mechanisms

Peng,

Ma,

Luo

et al. 2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

ObjectivesDigestive system diseases have evolved into a growing global burden without sufficient therapeutic measures. Lactobacillus reuteri (L. reuteri) is considered as a new potential economical therapy for its probiotic effects in the gastrointestinal system. We have provided an overview of the researches supporting various L. reuteri strains’ application in treating common digestive system diseases, including infantile colic, diarrhea, constipation, functional abdominal pain, Helicobacter pylori infection, inflammatory bowel disease, diverticulitis, colorectal cancer and liver diseases.MethodsThe summarized literature in this review was derived from databases including PubMed, Web of Science, and Google Scholar.ResultsThe therapeutic effects of L. reuteri in digestive system diseases may depend on various direct and indirect mechanisms, including metabolite production as well as modulation of the intestinal microbiome, preservation of the gut barrier function, and regulation of the host immune system. These actions are largely strain-specific and depend on the activation or inhibition of various certain signal pathways. It is well evidenced that L. reuteri can be effective both as a prophylactic measure and as a preferred therapy for infantile colic, and it can also be recommended as an adjuvant strategy to diarrhea, constipation, Helicobacter pylori infection in therapeutic settings. While preclinical studies have shown the probiotic potential of L. reuteri in the management of functional abdominal pain, inflammatory bowel disease, diverticulitis, colorectal cancer and liver diseases, its application in these disease settings still needs further study.ConclusionThis review focuses on the probiotic effects of L. reuteri on gut homeostasis via certain signaling pathways, and emphasizes the importance of these probiotics as a prospective treatment against several digestive system diseases.

show abstract

“…GM plays a pivotal role in the processes of nutrient metabolism and energy extraction [ 39 ]. However, when dysbiosis occurs, it can have detrimental effects on nutrient assimilation and metabolism, leading to conditions such as malnutrition or an imbalanced energy equilibrium [ 40 ]. The presence of altered gut microbiota leads to the disruption of the intestinal barrier function, which permits the passage of microbial components and harmful substances into the bloodstream [ 41 ].…”

Section: The Kidney Gm Crosstalkmentioning

confidence: 99%

Clinical Perspectives of Gut Microbiota in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: Where Do We Stand?

Pantazi,

Kassim,

Nori

et al. 2023

Biomedicines

View full text Add to dashboard Cite

The gut microbiota (GM) plays a vital role in human health, with increasing evidence linking its imbalance to chronic kidney disease and end-stage kidney disease. Although the exact methods underlying kidney-GM crosstalk are not fully understood, interventions targeting GM were made and lay in three aspects: diagnostic, predictive, and therapeutic interventions. While these interventions show promising results in reducing uremic toxins and inflammation, challenges remain in the form of patient-specific GM variability, potential side effects, and safety concerns. Our understanding of GMs role in kidney disease is still evolving, necessitating further research to elucidate the causal relationship and mechanistic interactions. Personalized interventions focusing on specific GM signatures could enhance patient outcomes. However, comprehensive clinical trials are needed to validate these approaches’ safety, efficacy, and feasibility.

show abstract

Probiotics for children with uncomplicated severe acute malnutrition (PruSAM study): A randomized controlled trial in the Democratic Republic of Congo

Cited by 8 publications

References 26 publications

Modulation of the Gut Microbiota with Prebiotics and Antimicrobial Agents from Pleurotus ostreatus Mushroom

Modulation of the Gut Microbiota with Prebiotics and Antimicrobial Agents from Pleurotus ostreatus Mushroom

Lactobacillus reuteri in digestive system diseases: focus on clinical trials and mechanisms

Clinical Perspectives of Gut Microbiota in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: Where Do We Stand?

Contact Info

Product

Resources

About